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Neurodegeneration with brain iron accumulation (NBIA)
is a group of disorders characterized by dystonia, parkin-
sonism and spasticity. Iron accumulates in the basal
ganglia and may be accompanied by Lewy bodies, axonal
swellings and hyperphosphorylated tau depending on
NBIAsubtype.Mutationsin10geneshavebeenassociated
with NBIA that include Ceruloplasmin (Cp) and ferritin
light chain (FTL), both directly involved in iron homeosta-
sis, as well as Pantothenate Kinase 2 (PANK2), Phos-
pholipase A2 group 6 (PLA2G6), Fatty acid hydroxylase 2
(FA2H), Coenzyme A synthase (COASY), C19orf12,
WDR45 and DCAF17 (C2orf37).These genes are involved
in seemingly unrelated cellular pathways, such as lipid
metabolism, Coenzyme A synthesis and autophagy. A
greater understanding of the cellular pathways that link
these genes and the disease mechanisms leading to iron
dyshomeostasis is needed. Additionally, the major overlap
seenbetweenNBIAandmorecommonneurodegenerative
diseasesmayhighlightconserveddiseaseprocesses.Inthis
review,wewilldiscussclinicalandpathologicalﬁndingsfor
each NBIA-related gene, discuss proposed disease mecha-
nisms such as mitochondrial health, oxidative damage,
autophagy/mitophagy and iron homeostasis, and specu-
late the potential overlap between NBIA subtypes.
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Introduction
Neurodegeneration with brain iron accumulation (NBIA)
is a group of neurodegenerative diseases characterized by
iron accumulation in the basal ganglia. Speciﬁcally,
excess iron accumulates in the globus pallidus (GP) and
the substantia nigra (SN) and can be visualized with
MRI. The cortex and the cerebellum can be affected, and
cerebellar involvement correlates with the most severe
NBIA subtypes. The SN and the GP naturally contain
high iron concentrations [1,2] and also have a high
metabolic requirement, potentially predisposing these
areas to iron-related damage.
Theaccumulationof ironhasneitherbeenproventobe
causenorsymptominNBIA.Ironcanshuttlebetweentwo
redox states and so is utilized by the cell for electron dona-
tion. ‘Free’ iron [the so called labile iron pool (LIP)] is
highly reactive and can be destructive to the cell via for-
mation of reactive oxygen species (ROS) [3]. For this
reason, there are precise homeostatic mechanisms to
tightly control iron levels in the cell (for central nervous
system review, see Rouault [4]; for peripheral systems, see
AndrewsandSchmidt[5]).Inthecentralnervoussystem,
extracellularironisboundbyTransferrinandinternalized
into the cell via Transferrin receptor-based endocytosis
and the channel DMT1. Cytosolic iron is stored in Ferritin
structures or transferred to organelles that are iron rich,
Correspondence: Charles Edward Arber, Department of Molecular
Neuroscience, Institute of Neurology, University College London,
LondonWC1N1PJ,UK.Tel:+44(0)2076794294;Fax:+44(0)203
448 4017; E-mail: c.arber@ucl.ac.uk
1 © 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction
in any medium, provided the original work is properly cited.
Neuropathology and Applied Neurobiology (2015) doi: 10.1111/nan.12242such as mitochondria. Mitochondria have devoted iron
importers and storage proteins. Cellular iron is exported
via Ferroportin with the support of ferroxidases:
Ceruloplasmin (Cp; mostly astrocytes) and Hephaestin
(widespread). Oxidative state is controlled by ferroxidases
through the pathway, such as DMT1, Ferritin and Cp.
Transcription of these iron homeostasis genes is con-
trolled closely via Iron Regulatory Protein 1/2, which
control expression based on cellular iron concentration
(reviewed [6]).
As well as iron accumulation, patients exhibit dystonia,
parkinsonism and spasticity. Genetically conﬁrmed patho-
logicalstudieshaveidentiﬁedproteinaggregatesandaxonal
swellings that are reminiscent of other common neuro-
degenerative disorders [7]. NBIA was previously known as
Hallervorden-Spatzdiseaseif onsetwasaftertheﬁrstdecade
of lifeandinfantile-neuroaxonaldystrophywithearlyonset;
however,geneticﬁndingsareredeﬁningthedisease.
Genetic screening over the last decade has identiﬁed
10 disease-associated genes which lead to NBIA; however,
around 20% of NBIA cases remain genetically unde-
ﬁned[8].Atﬁrstglance,these10genesappeartobeunre-
lated and are involved in diverse cellular pathways
(Figure 1). Only two genes are directly associated with
iron homeostasis.
A greater understanding of the NBIA genes and any
shared cellular function will ultimately help to link
commonclinicalpresentation,MRIﬁndingsanddisease
processes.Additionally,elucidatingdiseasemechanisms
thatleadtoNBIAmayberelevanttootherdiseasessuch
as frontotemporal dementia (FTD), Parkinson’s disease
(PD), Alzheimer’s disease (AD), Friedreich’s ataxia and
amyotrophic lateral sclerosis (ALS), which display
similar aspects of disease [9]. Thus, utilising the
monogenetic orphan diseases is of great use to deﬁne
disease processes that are involved in common and
genetically undeﬁned diseases.
Theclinicalfeaturesassociatedwiththevariousgenetic
causes of NBIA are outlined inTable 1, and the pathology
of NBIA is reviewed in Table 2. In this review, we will
discuss potential disease mechanisms for each gene defect
and ﬁnally propose potential cellular processes that link
the entire NBIA spectrum.
PANK2 and PKAN
Mutations in the Pantothenate Kinase 2 gene (PANK2)
lead to Pantothenate Kinase-associated neurodegenera-
tion (PKAN, NBIA type 1). PKAN represents the most
common genetic cause of NBIA and occurs in around
two-thirds of NBIA patients [10,32].
PANK2 is a seven exon gene which is alternatively
spliced to form two transcript variants [33]. Mutations
have been described throughout the gene leading to
autosomal recessive PKAN. There is a strong correlation
between loss of enzymatic activity and disease onset, for
example, two null mutations will present with an early-
onset phenotype [34,35]. Despite the fact that PANK2
proteins form homodimers, it is unlikely that mutant
PANK2 has a dominant negative effect, as co-expression
of mutant PANK2 and wild-type PANK2 shows similar
activity to wild-type PANK2 alone [33]. The most fre-
quent mutation is G521R which is thought to contribute
to 25% of the disease alleles [10], and this mutant
protein fails to fold properly, exhibiting no enzymatic
activity [33].
PANK2 is one of four human pantothenate kinase pro-
teins and is speciﬁcally located in the mitochondria
[36,37]. PANK4 is proposed to be nonfunctional
while PANK1 and PANK3 are active in the cytosol. The
PANK2 polypeptide contains a mitochondrial localization
signal. There is a catalytic ATP binding domain located
at the N-terminus of the protein and a domain of
unknown function at the C-terminus of the protein.
PANK2 homodimers are located in the mitochondrial
intermembrane space.
Pathology
Nine conﬁrmed PKAN patients have been studied post
mortem, exhibiting predominant GP pathology (Table 2)
[20,21]. In all cases, the GP was discoloured and showed
excess iron accumulation. Iron was distributed in degen-
eratingneurones,macrophages,astrocytes,microgliaand
also in perivascular regions. Neuronal cell loss was
evidentandlargelyrestrictedtotheGP,togetherwithasso-
ciated axonal loss. Astrogliosis of the GP was a common
feature.
Cortical and subcortical brain regions show axonal
swellings and spheroid bodies.These represent degenerat-
ing neurones and dystrophic axons. Swellings are immu-
noreactive at varying degrees for ubiquitin, amyloid
precursor protein and phosphorylated neuroﬁlament
[20,21]. A loss of myelin and vacuolization has been
described in the pallidum [21], potentially linking PKAN
disease processes to other demyelinating conditions.
2 C. E. Arber et al.
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on behalf of British Neuropathological SocietyTau pathology has been noted to a minor extent in all
cases, with tangles and threads present in the cortex
[21]. Historically, NBIA was thought to be an alpha-
synucleinopathy; however, genetic screening methods
have been distinguished PKAN, which shows no
α-synuclein accumulation, with other NBIA subtypes
that do, for example MPAN and PLAN (see below).
PANK2 mechanisms
The primary function of PANK is to catalyse the ATP-
dependent phosphorylation of dietary pantothenate
(vitamin b5) to 4-phosphopantethenate, the ﬁrst step in
Coenzyme A (CoA) biosynthesis. CoA is central to
metabolism and is required for β-oxidation, the citric acid
cycle and the metabolism of amino acids and ketone
bodies. CoA is also required for synthesis of fatty acids
and amino acids.
A prominent hypothesis for neurodegeneration caused
by PANK2 deﬁciency is that the lack of active enzyme
leads to build-up of substrates in the CoA biosynthetic
pathway.This leads to an accumulation of N-pantothenyl
cysteine and free cysteine. Cysteine build-up can chelate
Figure 1. Cellular localization of NBIA-associated genes. Iron (black circles) is taken up via transferrin-mediated endocytosis (upper right).
Cytoplasmic iron is stored in ferritin, made up of 24 monomers of ferritin light chain (FTL) and ferritin heavy chain. GPI-anchored
Ceruloplasmin (CP) facilitates Transferrin-mediated cellular export of iron. Free CP is also present in serum. Mitochondria and lysosomes
contain most of the total cellular iron. Pantothenate kinase 2 (PANK2) is a dimer and localized to intermembrane space of the
mitochondria. CoA Synthase (COASY) and C19orf12 are currently believed to reside in the inner mitochondrial membrane and the outer
mitochondrial membrane, respectively. COASY has a single transmembrane domain, and C19orf12 has two membrane spanning domains.
Phospholipase A2 G6 (PLA2G6) is a cytoplasmic tetramer that, upon activation, can be oleoylated and associated to the plasma membrane,
mitochondrial membranes, endoplasmic reticulum (ER) and nuclear envelope. WDR45 is a seven bladed β-propeller protein that binds to
phosphoinositol-3-phosphate-enriched membranes at the ER. Fatty acid hydroxylase 2 (FA2H) is a four-pass protein located in the ER.
ATP13A2 is a 10-pass polypeptide that resides in the lysosomal compartment (dark vesicles) and possibly the mitochondrial inner
membrane. Finally, DCAF17 is a single pass protein located in the nucleolus.
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on behalf of British Neuropathological Societyiron and lead to its accumulation. Free cysteine can auto-
oxidize in the presence of iron and produce ROS, resulting
in widespread oxidative damage and cell death, perhaps
through lipid peroxidation [32,38]. Iron content is natu-
rally high in the GP and SN [1], potentially sparking
degenerationsynergisticallywithexcesscysteine,followed
by a negative feedback of iron accumulation and ROS-
derived damage.
The localization of PANK2 at the mitochondria
(Figure 1) prompted several groups to investigate
mitochondrialdysfunctioninPKANpathogenesis.PANK2
mutant ﬁbroblasts [39] as well as mouse and ﬂy pank
knockout models [40–42] have hinted to mitochondrial
deﬁciencies, including reduced mitochondrial membrane
potential, swollen mitochondria with altered cristae and
ruptured membranes. ROS damage has been described
with varying degrees.
The loss of mitochondrial membrane potential can
affect the rate of mitophagy, and it is feasible that altered
mitochondrial ﬁssion and/or trafﬁcking, together with
membrane remodelling deﬁciencies due to lower levels of
CoA and acyl-CoA, might contribute to axonal swellings
[43,44].
Drosophila have one pantothenate kinase, fumbl. The
fumbl hypomorphic model displays locomotor defects and
lipid dyshomeostasis which are fully rescued by human
PANK2 [40]. This highlights the high degree of protein
conservation between species [45]. Importantly, human
PANK3 and PANK4, which are cytosolic proteins, cannot
fully rescue drosophila mutants, hinting to a cellular
dependence on speciﬁc PANK2 activity [45].
There is a rate limiting feedback inhibition step by acyl-
CoAs on the ATP binding pocket of PANK2 [34]. The
negative regulation of PANK2 by acetyl-CoA is so tight
thatmechanismsareinplacetorelievethisinhibition.For
example, palmitoylcarnitine activates PANK2 in physi-
ological conditions [46]. Enzymatic regulatory deﬁcien-
cies could thus be involved in disease. However, three
mutant proteins tested in vitro display similar acetyl-CoA
inhibition [33].
PANK2 may have a role in sensing CoA concentration
and the metabolic cross-talk between the mitochondria
and the cytoplasm [46]. This could explain why genetic
mutations not affecting enzymatic activity could lead to a
disease phenotype. In addition, pantothenate kinase-
derived CoA is responsible for acetylation of proteins [47].
Protein acetylation and CoA levels have been shown to
directly link cellular metabolism and autophagic ﬂux
[48,49]. This implicates a new pathway that is distinct
from the well-documented processes controlling
autophagy, including AMPK and mTOR1.
PANK2 mutations could disrupt a putative
mitochondrial-speciﬁc fatty acid synthase pathway –
critical for mitochondrial membrane assembly and func-
tion [37]. One study has conﬁrmed lipid dyshomeostasis
via a metabolomics approach on blood plasma of PKAN
patients [50]. Furthermore, the clinical overlap described
between PKAN and HARP syndrome (hypoprebetali-
poproteinaemia, acanthocytosis, retinitis pigmentosa
and pallidal degeneration), which both derive from muta-
tions in PANK2, strongly links lipid production deﬁcits in
PANK2 mutants [51].
It is important to consider the role of excess iron in
PKAN. PANK2 is targeted to the mitochondria, which are
amajorsinkof ironwithinthecells,andmultipleproteins
involved in the electron transport chain contain iron-
sulphurclusters.Knockdownof PANK2inHELAcellsand
hepatocytes leads to a marked induction of ferroportin
mRNA, the sole cellular exporter of iron [52]. Addition-
ally, patient ﬁbroblasts showed a reduced response to
excess iron, with reduced expression of ferritin (the cellu-
lar iron storage protein) and an increased LIP [39].
Increased labile iron could lead to ROS directly, due to the
Fenton reaction, whereby water is broken down in the
presence of iron to form ROS.
In summary, PKAN patients display excess iron deposi-
tion and neuronal cell death, primarily in the GP. PANK2
mutations might affect metabolism and lipid turnover and
ultimate affect energy production or mitochondrial
ﬁtness. Conversely, reduced CoA levels have not been
proven in patient tissue, and so, disease mechanisms
through alternate unknown PANK2 functions remain a
possibility. Investigations into cellular mechanisms of cell
death are required to understand the reasons for speciﬁc
degeneration due to this gene defect.
COASY and CoPAN
Mutations in the CoA Synthase (COASY) gene were
recently shown to lead to NBIA [11]. Clinically, COASY
protein-associated neurodegeneration (CoPAN) patients
display similar clinical features to PKAN patients
[11].
The COASY protein contains a mitochondrial localiza-
tion signal, a regulatory region and a domain for each of
the two catalytic kinase domains: adenyl transferase and
6 C. E. Arber et al.
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on behalf of British Neuropathological Societydephospho CoA. COASY is localized to the mitochondrial
matrix [11,53].There are two COASY isoforms, produced
from alternate splicing. The longer β isoform is brain spe-
ciﬁcandhasanadditionalproline-richproteininteraction
domain but has identical enzymatic activity to the ubiqui-
tous α isoform [54].
TwoCoPANmutationsdescribedbyDusiandcolleagues
represent a premature stop codon (G49Stop) and a muta-
tion affecting a conserved residue involved in ATP binding
and dephospho-CoA kinase activity (R499C). These are
proposed to completely abrogate the protein functionality
[55].
Interestingly, yeast knockout models for the two pro-
teins that are COASY orthologues lead to a lethal pheno-
type. Human wild-type COASY protein can rescue this
lethality, and mutant COASY from patients can rescue
knockout cells but lead to a higher requirement for
pantothenate in the growth media [11].
COASY mechanisms
COASY is in the same metabolic pathway as PANK2 and is
a bifunctional enzyme catalysing the ﬁnal two steps of
CoA synthesis [53,56]. Mutant COASY protein appears to
havenoactivityinvitro,whereasCoAlevelsinpatientand
control ﬁbroblasts appear normal [11].This suggests CoA
levels are maintained by either residual activity of the
COASY protein, or via an alternative, as yet unknown,
pathway for CoA synthesis.
The fact that COASY acts in the same pathway
as PANK2 suggests common mechanisms may be
shared between PKAN and COPAN, such as reduced
acyl-CoA and lipid synthesis leading to mitochondrial
insufﬁciencies.
Of the 10 NBIA-related genes, only COASY shows a
putative iron response element (IRE) via the SIREs 2.0
prediction tool (http://ccbg.imppc.org/sires/). The
sequence is a putative 3′ IRE and would lead to mRNA
stabilization in the presence of iron.This could potentially
link COASY expression to iron availability in the cell.
C19orf12 and MPAN
C19orf12 is a protein located on the outer mitochondrial
membrane with unknown function (Figure 1). Mutations
in C19orf12 lead to mitochondrial membrane protein-
associated neurodegeneration (MPAN). MPAN accounts
for around 30% of NBIA [22]. Other diseases associated
with C19orf12 mutations include pallido-pyramidal syn-
drome [57], hereditary spastic paraplegia type 43
(SPG43) [58] and ALS [59].
C19orf12 is a two-pass transmembrane protein with
two alternative start codons. Missense mutations have
been described to add charged amino acids to putative
hairpin domains, potentially disrupting the 3D structure
[12,58]. MPAN has been successfully modelled in
drosophila [60].
Post-mortem examination of two MPAN cases [12,22]
showedironaccumulationmainlyconﬁnedtotheGP.Iron
accumulationwasaccompaniedbyneuronalatrophy,and
depositions were present in neurones, macrophages and,
to a lesser extent, astrocytes (Table 2).
Lewy bodies and Lewy neurites were a characteristic
feature of MPAN with an extremely high burden [22].
Lewy neurites in the GP were adjacent to the atrophied
regionandLewypathologyextendedtotheSNwherethey
were associated with near complete neuronal loss. Lewy
bodies were also present in the cortex, striatum and
hippocampus.Axonalswellingsandhyperphosphorylated
tau were also present in the cortex, GP, caudate/putamen,
SN and brain stem. Demyelination was evident in the
spinal pyramidal tracts and optic nerve.
C19orf12 mechanisms
C19orf12 may be expressed in the ER as well as the mito-
chondria [58], and pathogenic mutations that lead to
SPG43 or MPAN alter the distribution of the protein,
potentially hinting to a lack of proper protein folding and
enzymatic activity. C19orf12 is expressed in neurones,
white blood cells and adipocytes [60]. During in vitro dif-
ferentiation of white blood cells, C19orf12 expression
closely follows fatty acid metabolism, suggesting a link to
lipid homeostasis [12]. It was further proposed that this
function could be associated with CoA metabolism,
linking MPAN to PKAN and CoPAN [12].
Therefore, C19orf12, PANK2 and COASY are linked
through mitochondrial localization, lipid metabolism and
ultimately iron deposition and Tau pathology in disease.
PLA2G6 and PLAN
Mutations in the gene encoding phospholipase A2 group
VI calcium-independent (PLA2G6, also known as
iPLA2β or iPLA2-VIA) have been associated with two dis-
eases: phospholipase associated neurodegeneration
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(Table 1). PLA2G6-associated disease may have previ-
ouslyrepresentedinfantileneuroaxonaldystrophy(INAD)
before NBIA reclassiﬁcation.
There are four groups of PLA2s containing more than
20 proteins: secreted PLA2s, calcium-dependent cytosolic
PLA2s, platelet-activating acetylhydrolases and calcium-
independent PLA2s (iPLA2) [61]. PLA2G6 is responsible
for 70% of total PLA2 activity in the brain [62].
The PLA2G6 gene encodes an 806 amino acid protein
with predicted size of 88 kDa. The mature protein is
tetrameric and composed of an ankyrin repeat domain
that is involved in protein interaction, a GXSXG lipase
motif, an ATP binding pocket and a Calmodulin binding
domain[61].Thereareatleastﬁvesplicevariants,threeof
which contain the lipase motif GXSXG, whereas two
contain only the ankyrin repeats and most likely act as
competitive inhibitors within the tetramer [63].
PLA2G6 has been shown to be expressed in the mito-
chondria [64,65] and be protective to mitochondrial
health[66].Expressionisalsoseenatthenuclearenvelope
and at axon terminals in primate brain tissue [67].
PLA2G6 is ubiquitously expressed [68], although disease
symptoms are solely neurological.
Autosomal recessive mutations are found throughout
PLA2G6 and lead to reduced enzyme activity [13]. The
magnitude of effect on enzyme activity correlates with
disease severity: two null copies of PlA2G6 have the most
severe phenotype [23]. Dystonia-parkinsonism mutations
do not affect the enzymatic ability of the protein but could
alter protein interactions [69].
The enzyme can undergo autoacylation by oleoyl-CoA
near the catalytic residue [70]. Acylation leads to a
cytosolic to membrane relocation of PLA2G6 and may
lead to precise subcellular targeting of the enzyme and
potential catalytic activation (Figure 1).
Pathology
The pathology of seven conﬁrmed PLAN cases have been
studied(Table 2).Themajorpathologicalhallmarkof PLANis
the presence of axonal swellings throughout the cortex, GP,
striatum, cerebellum, brain stem and spinal cord. These are
also present throughout the peripheral nervous system and
can be diagnostic via peripheral nerve biopsies. There is
evidence for PLA2G6 mutation-associated PLAN without
spheroids [13]. Peripheral spheroids are not observed in
dystonia-parkinsonismsubsetof PLANpatients[71].
Spheroids stain positive for phosphorylated neuro-
ﬁlament, ubiquitin and APP. α-Synuclein positive Lewy
bodiesarefoundthroughoutthedegeneratingbrainareas
to a very high degree, and a proportion of the axonal
swellingsalsostainedpositiveforα-Syn.Lewybodieswere
speciﬁcally seen in the SN pars compacta. Cases also
exhibitedadvancedtaupathologyinearlyadulthood[23–
25],wherebybraakstageV/VIneuroﬁbrillarytanglesand
neuropil threads were evident in cortical areas at the age
of 18 and 32 [25]. Granules within spheroids of pla2g6
mutant mice were positive for Periodic-acid Schiff (PAS)
staining. This is likely to represent polysaccharides,
glycated proteins or aldehyde products of ROS-damaged
lipids [72].
Tubulovesicular structures, another characteristic of
PLAN, are membrane-rich inclusions and thought to
contain mitochondria, lysosomal components, vacuoles,
endoplasmic reticulum as well as occasionally a protein
component [73].
Atrophy is evident in the cortex, GP, white matter, the
cerebellar granule cells and cerebellar purkinje cells and
was shown to be associated with gliosis in the cortex and
the striatum [25]. Excess iron deposition was speciﬁcally
observed in the GP and the SN pars reticulata [23].There
is extensive cortical involvement in disease, and Lewy
bodies are seen in all cases whereas tau deposition is rarer
[24,25].
PLA2G6 mechanisms
PLA2G6 hydrolyses glycerophospholipids at the sn-2
position of acyl chains to produce lysophospholipids
and free fatty acids, such as arachidonic acid. The
downstream metabolites of free fatty acids such as
leukotrienes and prostaglandin perform essential cellular
functions and contribute to a variety of signalling events
including membrane remodelling, fatty acid oxidation,
cell signalling and growth, and apoptosis [61]. The
2-lysophophospholipid may also play a role in signalling
such as in the production of platelet activating factor.
Phospholipase activity is crucial for membrane integrity
via phospholipid recycling and homeostasis.
PLA2G6-mediated neurodegeneration may occur via
the inability to remodel oxidized and damaged phospho-
lipids. Polyunsaturated mitochondrial components, such
ascardiolipin,areextremelysensitivetoROS.PLA2G6has
an increased afﬁnity to membranes in hydrogen peroxide-
treated cells resulting in a raised activity and increased
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ROS sequester PLA2G6 to the mitochondria, and this is
protectiveagainstapoptosis[66].Patientcellswereshown
to display faulty mitochondrial at the ultrastructural level
[75,76].
Uncoupling of the mitochondrial respiratory chain
and associated depolarization (e.g. in de-energized states
or after calcium ion inﬂux) can lead to activation of
PLA2G6 within the mitochondria and therefore free fatty
acid accumulation [77]. This can initiate apoptosis
through stimulating the permeability transition pore and
cytochrome C release leading to further lipid damage and
apoptotic signals [65,78]. Reduced PLA2G6 activity may
lead to dysregulation of this process.
Related to this, ER stress can increase the expression
and activity of PLA2G6, bringing about the loss of
mitochondrial membrane potential and increasing the
likelihood of apoptosis [79].
PLA2G6 plays an important role in membrane homeo-
stasis.The lipid proﬁle of spinal cords of Pla2g6 knockout
mice is greatly altered suggesting a defective remodelling
ability. This may be causal for degenerative inner
mitochondrial membranes and axonal termini [80].
Altered axonal and/or organellar membrane integrity
may lead to improper axonal transport and accumulation
of cellular components at distal axon locations, subse-
quentlyleadingtoaxonalblockageanddegeneration[81].
Both products of PLA2G6 catalysis, lysophospholipids
and free fatty acids, may be able to increase membrane
fusion via increased ﬂuidity and nonbilayer structures in
the local environment [61]. This could have important
roles in autophagy, mitophagy and other vesicle-based
processes that have been shown to be involved in
neurodegeneration.
Using pla2g6 knockout mice, Beck and colleagues pro-
posed that the disease progresses via two concurrent
mechanisms [80]. Firstly, mitochondria exhibit degenera-
tive inner membranes, and a large component of swell-
ings was shown to be mitochondria. Faulty mitochondria
transported through the axons may release ROS and
proapoptotic factors that damage neighbouring mem-
branes, producing axonal swellings. Degenerative
mitochondria are accompanied by local cytoskeletal dis-
appearance, exacerbating mitochondrial transport deﬁ-
ciencies. Secondly, at axon terminals, membranes and
synaptic vesicles degenerate and form swellings and
tubulovesicular structures. Together, the lack of mem-
brane remodelling is proposed as the cause of the disease
phenotypes seen within axons and at axon terminals,
two sites where PLA2G6 is localized [66,67].
Finally, there is evidence for a noncell autonomous
effect of PLA2G6 disruption. Docosahexaenoic acid
(DHA) is an essential fatty acid that cannot be synthe-
sized in neurones. Astrocytes have been shown to
produce and release DHA due to PLA2G6 action [82].
Knockdown of the enzyme in astrocytes leads to a reduc-
tion of arachidonic acid and DHA in neurones and
increased prostaglandin production [83], which could
lead to increased apoptosis [84].
Calcium signalling was shown to be defective in
astrocytes from pla2g6 mutant mice and in astrocytes
treated with a PLA2G6 inhibitor [85]. This suggests that
cross-talk between neurones and glia may be disrupted in
PLAN/INAD.
PLA2G6isclassiﬁedasaPDgene(PARK14),andalso,a
reductioninPLA2G6proteinlevelshasbeenshowninthe
brains of Alzheimer’s patients [86]. Intriguingly, the SN
showslowendogenouslevelsof PLA2G6,possiblyshowing
a vulnerability to lipid oxidation [87]. Mitochondrial
involvement, lipid turnover and Tau pathology are again
implicated in this NBIA subtype.
FA2H and FAHN
Fatty acid 2 hydroxylase (FA2H) mutations are linked to
leukodystrophy, hereditary spastic paraplegia (SPG35)
and NBIA [14,88,89].
FAHN is a recessive disease, and it has been shown for
SPG35-associated mutations that the enzyme is nonfunc-
tional [88]. FA2H is a 43 kDa membrane-bound protein,
residing in the ER [90]. The polypeptide has a C terminal
sterol desaturase domain, which contains an iron binding
histidinemotif andisresponsibleforcatalyticactivity,and
an N terminal cytochrome b5 haem-binding domain,
involved in redox activity and electron donation to the C
terminus [91,92].
Mouse knockout models provide a hint towards FAHN
pathology, whereby the CNS exhibits enlarged axons and
demyelination [93]; however, no human post-mortem
studies have been reported.
FA2H mechanisms
FA2H is an enzyme that catalyses the hydroxylation of
fatty acids at position 2 of the N-acyl chain (Figure 1).
2-Hydroxy-fatty acids are a precursor for Ceramide
Mechanisms of neurodegeneration with brain iron accumulation 9
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Societysynthesis, a critical component of myelin sheaths [90].
Inactivating mutations in FA2H is likely to affect normal
myelin production due to loss of the hydroxylase activity
of the enzyme. The late onset and slow progression are
consistent with this idea, analogous to demyelinating dis-
eases such as multiple sclerosis (MS).
Altered ceramide signalling may have roles in Lewy
body formation, and the role of ceramide in apoptosis and
neurodegeneration has been implicated [94,95]. Myelin
formation via FA2H is dependent on lysosomal acid
ceramidase and also fatty acid oxidation in peroxisomes,
potentially linking cellular compartments that are
common between NBIA genetic disorders.
FA2H also has a role in lipid signalling pathways that
can affect cell cycle and apoptotic pathways [92].
Iron storing Ferritin has been shown to associate with
myelin [96], and it was postulated that iron accumulation
in disease could be associated with faulty myelin affecting
Ferritin dynamics [14].
Axonal myelination may be a common factor between
NBIA subtypes. PANK2 and COASY are both involved in
CoA synthesis. CoA has many diverse cellular roles but is
critical for the generation of sphingolipids, another prin-
ciple component of myelin [50]. Defective myelination
may contribute to neuronal dysfunction and apoptosis
and is shared between several neurodegenerative diseases
such as MS.
WDR45 and BPAN
Mutations in the WD repeat domain 45 gene (WDR45)
were linked to a form of NBIA and termed β-propeller-
associated neurodegeneration (BPAN) [97].
Despite WDR45 being on the X chromosome, BPAN
does not follow normal X-linked dominant inheritance.
Both genders have similar clinical features, and the
disease is always sporadic. Disease-associated mutations
are predicted to lead to nonfunctional proteins, and
are presumed to be lethal for male embryos. Male BPAN
sufferers are presumed to have de novo mutations
and were shown to have somatic or germline mosaicism
[97].
One conﬁrmed BPAN patient has been studied post
mortem (Table 2) [15]. Iron deposition was strongest in
the SN but also evident in the GP, concurrent with cer-
ebral and cerebellar atrophy (purkinje and granule cells).
Axonal spheroids were present in the basal ganglia (espe-
cially the GP and the SN), and gliosis was prominent.
Tau-positive neuroﬁbrillary tangles were common in
the neocortex, putamen and the hippocampus, and less
common in the atrophied GP and SN. Amyloid-β plaques
and Lewy bodies were not evident [15]. Pathological
changes appear to affect the SN preferentially over the GP.
WDR45 mechanisms
WDR45 (also known as WIPI4) is a β-propeller scaffold
protein that has been predicted to have a role in
autophagy. WDR45 is a member of the WD40 protein
family, which provide a basis for protein–protein interac-
tions and perform cellular functions such as autophagy,
cellcycleprogressionandtranscriptionalcontrol.WDR45
binds to phospholipids and autophagy-related proteins
[98].
The functions of WDR45 have been investigated using
several models. Yeast have over 30 autophagy-related
genes(atg),of whichmanymammalianhomologueshave
beenfound.WDR45isoneof 4atg18homologues,critical
for autophagosome formation (WIPI1-4) [99]. atg18
binds the ER membrane via a phosphotidylinositide-3-
phosphate binding motif and facilitates downstream
protein complex formation [100] (Figure 1).
Phosphatidylinositol-3-phosphate (PI3P) is a critical
factor in autophagy and is a major component of
autophagosome membranes. Upstream signalling (e.g.
mTOR) controls PI3P and autophagic ﬂux. PI3P
may be involved in early membrane curvature and
autophagosome size. Therefore, WDR45 could regulate
autophagosome size and maturation [99]. The Caenor-
habditis elegans homologue of WDR45, epg-6, was shown
to be required for regulating early autophagosome size
and interacts with several other ATG-like genes [98].
Epg-6 recruits atg9 which is thought to supply lipids for
newly forming autophagosomes [101].
Lymphoid cells from ﬁve patients with truncated or
destabilized WDR45 protein show a blockage in
autophagic ﬂux when exposed to inhibitors or activators
of autophagy [102].
atg Molecules are transiently present on mitochondrial
outer membranes suggesting a link between WDR45
autophagosomes and mitochondrial function [103]. H2O2
and ROS generated in mitochondria perform an essential
role in oxidising and inactivating atg4 so that the
autophagosome may form [104], leading Scherz-Shouval
andElazartohypothesizeasignallinggradientthatallows
autophagy biogenesis in the vicinity of mitochondria.
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entation, suggest that iron accumulation is observed in
the SN early in disease progression, and GP iron accumu-
lation is a later event [15]. This is in contrast to other
NBIA subtypes.
Finally, genes involved in autophagy are disrupted in
other disease conditions. PD, Crohn’s disease, cancer and
spastic paraperesis have all been shown to have disrupted
autophagy [105]. The pathology of BPAN and the strong
involvement of the SN potentially support a shared
mechanism to PD.
ATP13A2 and Kufor-Rakeb Syndrome
Mutations in ATP13A2 lead to Kufor-Rakeb Syndrome,
which is a disease exhibiting juvenile onset parkinsonism
and dementia (PARK9) [106], neuronal Ceroid-
Lipofuscinosis [107] and NBIA [16].
Mutations in ATP13A2 are autosomal recessive and
cluster on the cytoplasmic domains, interfering with cata-
lyticactivity[108].Transmembranestretchesmayalsobe
affected and consequently the protein architecture.
There are no post-mortem studies of ATP13A2
mutation-associated NBIA. However, studies of sporadic
PD patients have shown that ATP13A2 staining is
increased in cortical and nigral neurones [108,109], and
ATP13A2 protein is found associated with Lewy bodies
[110]. Post-mortem studies of Kufor-Rakeb Syndrome
patients conﬁrm the atrophy seen with MRI and also
lipofuscinosis in neurones and glia of the cortex, basal
ganglia and cerebellum [107].
ATP13A2 mechanisms
ATP13A2 is a lysosomal P-type ATPase that functions as
divalent cation transporter. P-type ATPases are a large
family of transporters that also include calcium pumps,
proton pumps and phospholipid ﬂipases.This superfamily
consists of highly conserved, 10-pass transmembrane
proteins, which utilize the energy stored in ATP to trans-
port ions across membranes [111].
ATP13A2wasshowntobeassociatedwithmembranes
of thelysosome[108](Figure 1),althoughithasalsobeen
linked with mitochondrial and synaptic membranes
[109]. Knocking down the expression of ATP13A2 affects
thesizeandnumberof autophagosomes[109].Mutations
in ATP13A2 may cause a mislocalization of the protein to
the ER [112].
The overexpression of ATP13A2 in model organisms
has been shown to protect against potentially cytotoxic
environments such as α-synuclein overexpression
[112,113] and heavy metal ions including cadmium,
manganese, nickel and selenium [114]. Indeed, patient
ﬁbroblasts from ATP13A2 mutants displayed lysosomal
deﬁciencies that lead to cytotoxic effects in the presence of
α-synuclein [115] and zinc [116]. Intracellular manga-
nese levels were shown to be higher in cells with mutant
ATP13A2 compared with wild type, hinting to a reduced
secretion ability [112]. This may directly lead to
cytochrome C release from mitochondria and apoptosis.
The increased cytosolic heavy metal status of the
cell may be linked with the characteristic fragmented
mitochondrial phenotype witnessed in mutant cells
[109,117]. Patient-derived ﬁbroblasts and olfactory neu-
rones have exhibited fragmented mitochondria, reduced
ATP production, oxidative stress and mitochondrial DNA
lesions [118] that may be in part due to reduced intrac-
ellular free zinc levels and a sensitivity to environmental
zinc [117]. Transcription of zinc homeostatic genes is
upregulated in a compensatory manner.
Metal ions are enriched in acidic lysosomal compart-
ments and could be involved in destructive conditions
requiredfordegradationandrecyclingevents[119].Addi-
tionally,divalentmetaliontransportersareunfaithfuland
appear to function to transport a range of metal ions.
Although iron has not been shown to be directly
dysregulated in ATP13A2 deﬁcient cells, it will be inter-
esting to investigate this further due to the accumulation
seen in the putamen of Kufor-Rakeb patients.
Another P-type ATPase, ATP7B, is mutated in Wilson’s
disease. Upon elevation of cytoplasmic copper levels, wild-
type ATP7B translocates from the golgi to the lysosome
whereby it aids the loading of copper into lysosomes.
Copper-rich lysosomes are then secreted from the cell via
lysosomal exocytosis [120]. Wilson’s disease results from
dysfunctional ATP7B, increased copper levels and altered
redox state. Therefore, the faulty ATP13A2 protein may
reduce a noncanonical cellular excretion mechanism for
heavy metals (Figure 2).
Post-mortem studies of NBIA-associated ATP13A2
patientbrainshavenotbeendescribedbutwillbeinforma-
tive with regard to pathological hallmarks. The fact that
ATP13A2 is a lysosomal disorder means that there are
tantalising links to lysosomal storage diseases. Addition-
ally, patients exhibit dementia and cortical atrophy, and
iron accumulation in the caudate and the putamen,
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subtypes, there is an effect on mitochondrial health.
DCAF17
DCAF17 (also called C2orf37) is a protein of unknown
function that is expressed in the nucleolus (Figure 1).
Mutations in this gene lead to Woodhouse-Sakati syn-
drome (WSS), and a subset of patients displays brain iron
accumulation [17]. Many patients display no iron accu-
mulation;however,theGPandtheSNareaffectedinsome
patients [8].
WSS manifests during adolescence and presents with
extrapyramidalsymptoms,dystoniaandcognitivedecline.
Typically, patients exhibit hypogonadism, alopecia and
diabetes mellitus.
Very little is known about the function of DCAF17;
however, the clinical phenotype of the patients and the
expression data are very similar to the ribosomal synthe-
sis deﬁciencies of patients with RBM28 mutations [121].
DCAF17 is a multipass transmembrane protein that is
named due to protein–protein interactions, Ddb1 and
Cul4-associated factor (damaged DNA binding protein 1
and cullin 4 ubiquitin ligase complex) [122]. This asso-
ciation links DCAF17 to protein ubiquitination involved
in DNA damage and cell cycle control. The nucleolar
localization leads to intriguing questions about speciﬁc
function and any links to other NBIA-linked mutations.
Figure 2. Cellular iron homeostasis and putative involvement of NBIA-associated genes. Iron is taken up via transferrin-mediated
endocytosis and a theorized cytoplasmic pool of free iron is termed the LIP. Free iron is safely stored within Ferritin macromolecules, via
Ferritin heavy chain and FTH. Cellular iron export is facilitated via the ferroxidase activity of Ceruloplasmin. High iron concentration is
required in mitochondria; however, no mitochondrial iron exporter has been found. Mitophagy is one potential mechanism for iron
recycling, and several NBIA-related genes may alter the rate of mitophagy, PANK2, COASY, C19orf12 and PLA2G6. Autophagy and
mitophagy are intrinsically related, and WDR45 mutations may alter the rate of these recycling processes. FA2H and PLA2G6 may impinge
on autophagy via membrane remodelling and vesicle formation. ATP13A2 has a role in divalent ion transport into the lysosome
compartment, and this could include/affect iron transport into the iron-rich lysosomal compartment. DCAF17 has not been linked to iron
homeostasis. Mitochondrial-rich vesicles have been described to be exocytosed and, together with theorized lysosomal-derived exosomes, may
represent another cellular iron secretory mechanism. Grey arrows represent theorized steps in the pathway. Black circles represent iron.
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Many transition metal ions are critical cellular compo-
nents.Ironisanessentialdietarycomponentandactsasa
crucial cofactor for enzymes and proteins. Iron is synthe-
sized into iron-sulphur clusters and haem groups
to perform catalytic events, and for example, 12 iron-
sulphur clusters and seven haem groups are required for
the mitochondrial respiratory chain.
Iron is present in two oxidative forms, ferrous Fe(II) and
ferric Fe(III), enabling effective electron transport. Iron
that is not bound into iron-sulphur clusters or haem
groups is termed the theoretical LIP. Free ferrous iron can
be extremely reactive, producing hydroxyl radicals and
leading to oxidative damage. Therefore, there exists tight
control over iron metabolism within the cell, whereby
entry, exit, redox state and total iron content are tightly
controlled (for review, see Rouault [4]). Haem consists of
an iron atom at the centre of an organic porphyrin ring
and has a distinct cellular metabolic pathway.
Twoformsof NBIAarearesultof mutationstoproteins
directly involved in cellular iron homeostasis, suggesting
that iron metabolism defects might be causative for NBIA.
Importantly, the GP and the SN are naturally rich in
iron, and iron content increases with age [1,2]. This may
predispose these brain regions to iron-induced damage in
NBIA disorders.
Cp and aceruloplasminaemia
Cp is involved in cellular iron export. Cp is a glycoprotein
containing many copper atoms (and potentially iron
atoms) that acts as a ferroxidase to facilitate ferroportin-
mediatedcellularironexport(Figure 1).Oxidationof Fe(II)
toFe(III)enablesbindingtotransferrinfortransportinthe
extracellularenvironment.Aceruloplasminaemia,leading
to brain iron accumulation, has been shown to be associ-
ated with a lack of ferroxidase activity (reviewed [123]);
however, mutant Cp protein accumulation has also been
described [124].
Disease is thought to progress as a lack of Cp-based
ferroxidaseactivityleadstoreducedcellularexportof iron
aswellasanaccumulationof extracellulartransferrin-free
Fe(II) [125]. Astrocytic sequestration of nontransferrin
bound extracellular iron could lead to a dearth of iron
available for neurones and subsequent cell death [126].
Importantly,othercelltypessuchasastrocytescontainan
alternative export-associated ferroxidase, Hephaestin,
and may explain speciﬁc regional degeneration in
aceruloplasminaemia [127].
Aceruloplasminaemia patients display increased serum
nontransferrin-bound iron, MRI-based evidence of iron
accumulation in the basal ganglia, movement disorders
and dementia. Pathology includes iron deposition in neu-
rones and glia within the basal ganglia and dentate
nucleus (Table 2) [26–28]. The retina and cerebellum
may also show iron accumulation as well as the cortex in
late stage disease. Astrocytes show spheroid-like globular
structuresandiron-richinclusionsintheirprocesses[26].
Oxidative damage was shown to be increased in patient
tissue, possibly due to increased reactive ferrous iron
[128].
FTL and neuroferritinopathy
Ferritin is the major storage protein for cellular iron
(Figure 1). Twenty-four monomers consisting of the
heavy and light chain subunits form a proteinaceous shell
that stores iron. Ferritin can store up to 4500 iron atoms.
The heavy chain has a ferroxidase activity, and the light
chain aids mineralization within the ferritin structure.
Mutations that affect the ferritin light chain (FTL) lead
to the autosomal dominant disease neuroferritinopathy.
The most common insertion mutation may lead to a poi-
soning of the holo-ferritin structure, potentially at the
iron entry pore [129], leading to an iron-porous ferritin
structure [130].
Iron deposition has been described throughout the
basal ganglia from MRI studies [131]. Importantly, evi-
dence of iron deposition has been seen in presymptomatic
familial carriers of the disease, leading to the hypothesis
that iron accumulation begins in childhood and worsens
until symptoms begin, in the fourth decade of life [132].
Pathological investigations have shown ferritin inclu-
sions are present in glia and neurones, as well as con-
ﬁrming iron deposition [19,30,31]. Neurones and glia
exhibit Ferritin inclusions in the putamen, GP, thalamus
and cerebellum. In the cortex, inclusion-positive glia
were perivascular and perineural. Aggregates stain posi-
tive for ferritin heavy chain, FTL, iron and ubiquitin.
Neuroaxonal swellings have been described, displaying
ubiquitin reactivity.
Mitochondrial abnormalities have been highlighted,
and an increased oxidative stress of the cells, possibly
due to iron, was shown via peroxidation and nitrosy-
lation [31]. Indeed, several animal and cell systems have
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models: through mitochondrial and nuclear DNA
damage, proteasomal insufﬁciencies, and damage to pro-
teins and lipid via reactive species [133–135]. Iron
chelators were able to reverse cell sensitivity, promoting
iron as the main cause of disease [133].
Unifying theories
Despite the fact that mutations in a diverse range of genes
lead to NBIA, there are several emerging themes that hint
of a mechanistic overlap across the NBIA spectrum:
mitochondrial involvement, ROS damage, lipid metabo-
lism, iron and autophagy.
Iron
One major question that remains unanswered is whether
iron accumulation is causative or symptomatic of NBIA.
Iron accumulation is not speciﬁc to NBIA but is observed
in a range of neurodegenerative disorders including AD,
HD and PD. This excess iron leads to increased oxidative
stress and neuronal toxicity.
CpandFTLhaveadirectroleinthecellularironhomeo-
static pathway. It seems rational that mutations in these
genes will lead to iron accumulation; for example, mutant
Cp leads to increased transferrin-free iron and uncon-
trolled cellular uptake [125].
Other NBIA genes seem more obscure with regard to
iron homeostasis, but similar neuropathology and gross
clinical symptoms could argue that mechanisms are con-
served between all NBIA subtypes. Contrary to this is the
argument that single gene defects such as PLA2G6 lead to
distinct diseases with variable iron accumulation. Indeed,
iron chelation therapy was able to reduce iron deposition
on MRI in PKAN patients but did not lead to clinical
beneﬁt [136], suggesting that iron accumulation is not
causative of symptoms in NBIA. One explanation for this
is that iron accumulation could be indirectly associated
withdisease.Divalentmetalionshavesimilarpropertiesin
cells, and iron dysregulation may affect the steady state of
other metal ions – such as zinc or copper leading to
neurodegeneration [137].
Iron dyshomeostasis could be explained from a faulty
mitochondrial component, as many NBIA-related genes
implicate mitochondria. Mitochondria can act as a cellu-
lar iron sink with a dedicated mitochondrial ferritin and a
series of enzymes requiring iron and haem for function.
However, there has been no discovery of a mitochondrial
iron exporter. Therefore, it appears the major mechanism
for iron recycling is via mitophagy and lysosomal degra-
dation of iron-containing proteins (Figure 2) [138].
Indeed, techniques for staining iron primarily depict iron
in lysosomal compartments [139]. Altered mitochondrial
ﬁtness may therefore alter mitophagic rates and so iron
turnover.
Lipid metabolism
Severalof theNBIAgenessuggestalteredlipidmetabolism
as a potential disease mechanism: PANK2, COASY,
PLA2G6, FA2H and potentially C19orf12. Altered lipid
metabolism would affect synthesis and remodelling of
lipid bilayers, and Kotzbauer et al. hypothesized a
mitochondrial speciﬁc fatty acid synthase pathway, which
could employ these genes for membrane remodelling and
mitochondrial function [37].
Distortion of mitochondrial cristae structure is evident
in some NBIA mutant conditions, and it is has been theo-
rized that respiratory chain super structures might be
disrupted as a result of lipid insufﬁciencies [41].
Mitochondrial membrane abnormalities could explain the
respiratory deﬁciencies and ROS damage seen in many
NBIA subtypes, and gradually lead to neuronal death.
Lipid metabolism may have a central role in myelin pro-
duction, and alterations could lead to neurodegeneration.
FAH2isinvolvedinceramideproduction,andbothPANK2
and COASY are required for sphingomyelin production,
demonstratedasPANK2mutationcarriershavedecreased
sphingosine and cholesterol [50], two critical components
of myelin.
Autophagy and mitophagy
Lipid metabolism can be linked with autophagy-
associated WDR45 and ATP13A2 via the endosome-
autophagolysosomepathways.Itisconceivablethatgenes
involvedinlipidmetabolismarerequiredtoconstructlipid
bilayers for autophagosome vesicle formation. Mitochon-
driamayrepresentanintersectionof lipidmetabolismand
autophagy. Not only have mitochondria been shown to
donate membranes to autophagic vesicles but also
autophagy-associated proteins are transiently seen on
mitochondrialoutermembranes[103].Mitochondrial-ER
contact sites may be critical for this process [140],
although this theory is still controversial [141].
14 C. E. Arber et al.
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological SocietyIn yeast, mitochondrial health requires one of either
mitochondrial-ER connections, or mitochondrial-vacuole
connections (the yeast lysosomal orthologue) [142].
These contacts are critical for lipid, calcium and amino
acid transfer, yeast health, and metabolic status [143].
This again hints that mitochondria and component recy-
cling are critical for cellular health.
It is tempting to speculate iron-laden autophagoly-
sosomes can also link into an exocytosis pathway
(Figure 2). Mitochondria were recently shown to be
exocytosed for astrocytic degradation [144]. This could
explain neuronal and glial susceptibility for iron deposi-
tion in affected brain regions. For example, defective mito-
chondria (PANK2, COASY, PLA2G6, C19orf12)m a yb e
packaged into early autophagosomes via WDR45.
ATP13A2 might load autophagic vesicles rich in mito-
chondriawithexcessironfromthecytoplasm.Thesecould
then be secreted and recycled in neighbouring astrocytes.
Unconventional modes of exocytosis are used in several
mammalian systems, for example, interleukin secretion
[145], and yeast unconventional exocytosis requires
autophagic vesicles and acyl-CoAs: yet another role for
CoA [146,147].
Unfolded protein response
Tau, α-synuclein, Cp and FTL have all been shown to
produce cellular inclusions in NBIA tissue.Taken together
with the presence of Ubiquitin in the axonal swellings
described in NBIA, the unfolded protein response could be
central to cell death in NBIA [148].
Axonal swellings and tubulovesicular structures are
another common theme. Components of these patholo-
gical hallmarks include mitochondrial components,
ubiquitinatedproteinsandcytoskeletalalterations.Poten-
tial mechanisms of cellular disturbance include local sites
of oxidative damage, for example, due to axonal transport
defects, local mitochondrial ROS production and mem-
brane damage [80,81].
Energetics
Finally,theenergeticstateisimplicatedthroughoutNBIA.
Mitochondrial health, together with CoA metabolism and
lipidhomeostasisallpointtowardsthemetabolismof fatty
acids and amino acids. Insufﬁciencies of mitochondrial
energy production and generation of ROS could point to
defective metabolism and subsequent oxidative damage
[149]. Acetyl-CoA concentration and COASY protein
complexeshaverecentlybeenshowntobecellularsensors
of energy status and can directly bridge metabolic state
and autophagic ﬂux through CoA concentration [48,49],
further linking PANK2 and COASY to WDR45 and
ATP13A2.
Overlap between NBIA disorders and other neuro-
degenerative disorders is seen via neuropathological evi-
dence of tau and synuclein aggregates, through clinical
manifestationsandalsoirondyshomeostasis.Itistempting
to consider shared mechanisms between NBIA, PD, FTD
andALS.ThefactthatNBIAisoftenchild-onsetmayhigh-
light speciﬁc mechanisms that go awry in late-onset dis-
eases due to a reduction of putative ‘coping mechanisms’
fornaturalstressors.Therefore,mechanismslinkingNBIA
neurodegeneration among subtypes may bring to light
important insights into neuronal health and ageing.
Conclusions
Using rare, penetrant and genetically deﬁned disorders to
understand disease mechanisms can help to make more
general conclusions. Cellular processes that lead to
neurodegeneration may be shared between a range of
neurodegenerative diseases, reinforced by similar patho-
logical and clinical ﬁndings.
The speciﬁc susceptibility of the GP to iron accumula-
tionleadingtomovementdisordersisintriguingduetothe
ubiquitous expression of the 10 NBIA genes. This may
point to a speciﬁc high iron content of the GP [2], a reli-
ance on iron-rich glial support cells or due to the tonic
activity of the GP, a very high metabolic demand. Retinal
cells also have a high metabolic rate and are often affected
in NBIA patients.
The involvement of the cerebellum correlates with
disease severity, e.g. PLAN and FAHN. Additionally, the
early involvement of the SN (e.g. BPAN) might stratify the
NBIA genes into Parkinsonian-like and dementia-like cat-
egories, helping to explain the Lewy body and tau-positive
and negative NBIA subtypes.
Future experiments will explain why cellular coping
mechanismsaredevoidinNBIAmutations,andtheseper-
turbations will be of huge interest to more common
neurodegenerative studies.
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